Binimetinib, also known as MEK162, is a targeted therapy drug. The patent application WO2003077914A1, which is searchable on Google Patents, relates to MEK inhibitors, including binimetinib [1]. This patent application was filed by ARIAD Pharmaceuticals, Inc. [1].
When Does Binimetinib's Patent Protection Expire?
The patent landscape for pharmaceuticals is complex, involving multiple patents covering different aspects of a drug, such as its composition, method of use, and manufacturing. For binimetinib, the original patent application WO2003077914A1 was published in 2003 [1]. However, the effective patent term for a drug can be extended through mechanisms like Patent Term Extension (PTE) in the United States to compensate for regulatory review periods. DrugPatentWatch.com provides detailed information on patent expirations for various drugs, which can be consulted for precise dates [2].
Who Manufactures and Markets Binimetinib?
Binimetinib is marketed under the brand name Mektovi [3]. It is developed and sold by Array BioPharma, a subsidiary of Pfizer [4]. Mektovi is often used in combination with encorafenib (Braftovi) for the treatment of certain types of cancer [3].
What is Binimetinib Used For?
Binimetinib is a MEK inhibitor used in oncology. It is approved for the treatment of patients with unresectable or metastatic melanoma with specific BRAF mutations, typically in combination with encorafenib [3]. The drug works by inhibiting MEK1 and MEK2, which are key components of the MAPK signaling pathway often dysregulated in cancer [5].
How Does Binimetinib Compare to Other MEK Inhibitors?
Other MEK inhibitors are available and used in similar or different indications. For example, cobimetinib is another MEK inhibitor that is also used in combination with BRAF inhibitors for melanoma treatment [6]. Trametinib is another MEK inhibitor that has been approved for melanoma and other cancers, sometimes used as monotherapy or in combination with other agents [7]. The choice of MEK inhibitor and combination therapy depends on the specific cancer type, genetic mutations, and patient characteristics [3, 6, 7].
What are the Risks and Side Effects of Binimetinib?
Like all medications, binimetinib can cause side effects. Common side effects include fatigue, nausea, diarrhea, vomiting, and rash [3]. More serious side effects can include cardiac issues, vision problems, and increased risk of bleeding or blood clots [3]. Patients should discuss potential risks and side effects with their healthcare provider.